According to the data compiled by the financial reporting tool of the trend stock selection system, as of the third quarter of 2022, Livzon Group ranked first in the gross profit rankings of listed companies with nucleic acid testing reagents, with gross profits reaching 2.105 billion yuan; Da'an Gene ranked second with a gross profit of 1.885 billion yuan; Dean Diagnostics ranked third with a gross profit of 1.78 billion yuan. Ranking in the top 10 are: Mingde Biotech, Watson Biotech, Cap Biotech, Shengxiang Biotech, Runda Medical, BGI, and Shuoshi Biotech.
NO.1, Livzon Group: 2.105 billion yuan Company location: Guangdong Industry: Pharmaceutical manufacturing company achieved total revenue of 3.186 billion in the third quarter of 2022, a year-on-year increase of 1.66%; gross profit was 2.105 billion, Gross profit margin is 66.08%.
NO.2, Da'an Gene: 1.885 billion yuan Company location: Guangdong Industry: Medical devices Da'an Gene's quarterly report for the third quarter of 2022 shows that the company achieved total operating income of 2.66 billion yuan, a year-on-year increase of 23.46 %; realized gross profit of 1.885 billion yuan and gross profit rate of 70.89%.
NO.3, Dean Diagnostics: 1.78 billion yuan Company location: Zhejiang Industry: Medical services Dean Diagnostics’ quarterly report for the third quarter of 2022 shows that the company achieved total operating income of 4.876 billion yuan, a year-on-year increase of 3.748 %; realized gross profit of 1.78 billion yuan and gross profit margin of 36.5%.
NO.4, Mingde Biology: 1.536 billion yuan Company location: Hubei Industry: Medical device company The third quarter quarterly report of 2022 shows that total revenue in the third quarter of 2022 was 2.217 billion, a year-on-year increase 178.14%; realized gross profit of 1.536 billion and gross profit rate of 69.29%.
NO.5, Watson Bio: 1.217 billion yuan Company location: Yunnan Industry: Biological products The company achieved total revenue of 1.358 billion in the third quarter of 2022, a year-on-year increase of 74.24%; gross profit was 1.217 billion , gross profit margin is 89.58%.
NO.6, Kaipu Biotech: 956 million yuan Company location: Guangdong Industry: Medical equipment Kaipu Biotech achieved total revenue of 1.416 billion in the third quarter of 2022, a year-on-year increase of 104.33%; gross profit 956 million, with a gross profit margin of 67.49%.
NO.7, Shengxiang Biological: 802 million yuan Company location: Hunan Industry: Medical device company The third quarter quarterly report of 2022 shows that total revenue in the third quarter of 2022 was 1.378 billion, a year-on-year increase 11.25%; realized gross profit of 802 million, gross profit rate 58.21%.
NO.8, Runda Medical: 798 million yuan Company location: Shanghai Industry: Medical services Runda Medical In the third quarter of 2022, the company achieved total revenue of 2.873 billion, a year-on-year increase of 19.88%; Gross The profit was 798 million, with a gross profit margin of 27.76%.
NO.9, BGI: 767 million yuan Company location: Guangdong Industry: Medical devices In the third quarter of 2022, BGI achieved total revenue of 1.353 billion, a year-on-year increase of -10.17%; Gross profit was 767 million, and gross profit margin was 56.73%.
NO.10, Shuoshi Bio: 632 million yuan Company location: Jiangsu Industry: Medical device company achieved total revenue of 1.028 billion in the third quarter of 2022, a year-on-year increase of -1.32%; gross profit was 632 million , gross profit margin is 61.52%. All information content on Southern Fortune Network does not constitute investment advice. The stock market is risky, so investment needs to be cautious.